Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Neuromuscular blockade reversal

PreclinicalSmall molecule

OOhio State University

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postoperative IleusRecruiting

Postoperative IleusPreclinical

Recruiting

Timeline

Expected Milestones

Q3 2027

Postoperative Ileus

NCT05344417

Clinical

Trials by Indication[1]

Postoperative Ileus1 trial

Low Pressure Pneumoperitoneum and Postoperative Ileus

Recruiting·OOhio State University·N/A·NCT05344417·125 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Neuromuscular blockade reversal. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neuromuscular blockade reversal compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neuromuscular blockade reversal. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ohio State University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: OOhio State University

Related News